3D Tumor Models

The TumorGraft3D platform is an advanced cancer research tool leveraging Patient-derived Xenograft models to generate a three-dimensional (3D) culture system. Developed by Champions Oncology, this platform allows researchers to study tumor biology and drug responses in a setting that closely mimics the in vivo environment. By maintaining the complex architecture and cell-cell interactions of the original tumor, TumorGraft3D provides more accurate and predictive data for evaluating cancer therapies, bridging the gap between traditional two-dimensional cell cultures and animal models.

The TumorGraft3D platform is an ex vivo system. It involves culturing tumor tissues or cells outside of the living organism in a controlled laboratory environment. Unlike in vivo models, where the tumor grows within an animal, TumorGraft3D maintains the tumor’s natural 3D structure and microenvironment in an ex vivo setting, allowing for detailed studies of tumor behavior and drug response in a rapid and cost-effective manner, while still retaining the clinical and biological relevance of the models.

TumorGraft3D models stand out from other cell-based platforms due to their ability to preserve the native 3D architecture and cellular heterogeneity of the tumor. While traditional 2D cell cultures often fail to replicate the complexities of in vivo tumors, TumorGraft3D models maintain the intricate cell-cell and cell-matrix interactions that are critical for accurate drug testing and biomarker discovery. By only using clinically relevant and low-passage models, this platform provides more biologically relevant data, leading to better predictions of clinical outcomes. Additionally, TumorGraft3D allows for the co-culture of multiple cell types, further enhancing its ability to mimic the tumor microenvironment.

To initiate a TumorGraft3D study with Champions Oncology, you can follow these steps:

1. Consultation: Contact Champions Oncology to discuss your research objectives and determine how the TumorGraft3D platform can be tailored to meet your specific needs.

2. Proposal Development: Champions will work with you to develop a detailed study proposal, outlining the experimental design, model selection, timelines, and deliverables.

3. Study Agreement: After finalizing the study plan, a formal agreement will be made to outline the terms of the collaboration.

4. Test Agent Shipment: Champions team will work with you on drafting a protocol and provide information on the amount of test agent required.

5. Study Execution: Champions will conduct the study, providing regular updates and detailed data analysis as the research progresses.

6. Data Delivery: Upon completion, Champions scientific team will provide a comprehensive overview of the data generated and help you plan your next experimental steps. You will also receive a comprehensive report with the study’s findings, including i drug efficacy, and potential biomarkers.

   Initiating a study with Champions Oncology ensures that you have access to cutting-edge technology, unparalleled models,  and expert guidance throughout your research project.

Yes. Our hematology panel includes patient-derived leukemia and lymphoma models with bone marrow and peripheral blood endpoints.